1 | B (migalastat) | 1件: Migalastat Migalastat | 1件: D10359
D10359
| - | - | 1件: 19 19 |
2 | B / Phuket / 3073/2013-like virus) | - | - | - | - | 1件: 53 53 |
3 | B-CIT and SPECT imaging | - | - | - | - | 1件: 6 6 |
4 | B-lines SE | 1件: Flunarizine Flunarizine | 2件: D01303
D01303
,
D07971
| 3件: CACNA1G CACNA1G, CACNA1H, CACNA1I 💬 | 8件: Aldosterone synthesis and secretion Aldosterone synthesis and secretion, Calcium signaling pathway, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, GnRH secretion, MAPK signaling pathway, Type II diabetes mellitus 💬 | 3件: 58 58, 86, 215 |
5 | B-Lymphocyte Stimulator (BLyS) | - | - | - | - | 1件: 65 65 |
6 | B-peptide-CRM197 conjugate | 1件: Corynebacterium diphtheriae CRM197 protein Corynebacterium diphtheriae CRM197 protein | - | - | - | 1件: 11 11 |
7 | B-STN DBS | - | - | - | - | 1件: 6 6 |
8 | B. lactis B94 | - | - | - | - | 1件: 193 193 |
9 | B. theta | - | - | - | - | 1件: 96 96 |
10 | B001 injection | - | - | - | - | 1件: 13 13 |
11 | B03BB01 | 1件: Folic acid Folic acid | 1件: D00070
D00070
| - | - | 1件: 46 46 |
12 | B2-ASmedic | 1件: Riboflavin Riboflavin | 3件: D00050
D00050
,
D01622
,
D01913
| - | - | 1件: 97 97 |
13 | B6, B12, L-methylfolate | 1件: Cyanocobalamin Cyanocobalamin | 4件: D00166
D00166
,
D03615
,
D03616
,
D03617
| - | - | 1件: 6 6 |
14 | B: 2 dosis | - | - | - | - | 1件: 97 97 |
15 | Bacille Calmette-Guerin vaccine | - | - | - | - | 1件: 13 13 |
16 | Bacille of Calmette-Guerin | - | - | - | - | 1件: 13 13 |
17 | Background Treatment | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
18 | Baclofen | 1件: Botulinum toxin type A Botulinum toxin type A | 1件: D00783
D00783
| 1件: SNAP25 SNAP25 💬 | 2件: Insulin secretion Insulin secretion, Synaptic vesicle cycle 💬 | 7件: 2 2, 10, 13, 18, 65, 149, 206 |
19 | Baclofen 20 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
20 | Baclofen ER Capsules (GRS) 10 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
21 | Baclofen ER Capsules (GRS) 20 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
22 | Baclofen ER Capsules (GRS) 30mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
23 | Baclofen ER Capsules (GRS) 40mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
24 | Baclofen ER Capsules (GRS) 50 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
25 | Baclofen IR | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
26 | Baclofen Tablets USP | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
27 | Baclofen Tablets USP 10 mg | 1件: Baclofen Baclofen | 1件: D00241
D00241
| 2件: GABBR1 GABBR1, GABBR2 💬 | 7件: Estrogen signaling pathway Estrogen signaling pathway, GABAergic synapse, GnRH secretion, Morphine addiction, Neuroactive ligand-receptor interaction, Taste transduction, cAMP signaling pathway 💬 | 1件: 13 13 |
28 | BACLOFENE | 1件: Naltrexone Naltrexone | 2件: D02095
D02095
,
D05113
| 3件: OPRD1 OPRD1, OPRK1, OPRM1 💬 | 5件: Estrogen signaling pathway Estrogen signaling pathway, Morphine addiction, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 10 10 |
29 | Bacteriophage | - | - | - | - | 1件: 65 65 |
30 | Bacteriophage preparation | - | - | - | - | 1件: 96 96 |
31 | Bacteriotherapy | - | - | - | - | 2件: 96 96, 97 |
32 | Bactrim | 1件: Doxycycline Doxycycline | 5件: D00307
D00307
,
D02129
,
D03903
,
D03904
,
D07876
| - | - | 1件: 299 299 |
33 | BAF312 | - | - | - | - | 2件: 13 13, 50 |
34 | BAF312 0,25 mg tablet | 1件: Levonorgestrel Levonorgestrel | 1件: D00950
D00950
| 1件: PGR PGR 💬 | 5件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation 💬 | 1件: 13 13 |
35 | BAF312 0,5 mg tablet | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 50 50 |
36 | BAF312 0.25 mg | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 50 50 |
37 | BAF312 0.25 mg tablet | - | - | - | - | 1件: 50 50 |
38 | BAF312 0.25mg tablet | - | - | - | - | 1件: 50 50 |
39 | BAF312 0.5 mg | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 50 50 |
40 | BAF312 0.50 mg | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 50 50 |
41 | BAF312 1 mg | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 50 50 |
42 | BAF312 1 mg tablet | - | - | - | - | 2件: 13 13, 50 |
43 | BAF312 1mg | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 50 50 |
44 | BAF312 1mg tablet | - | - | - | - | 1件: 50 50 |
45 | BAF312 2 mg | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 50 50 |
46 | BAF312 2 mg tablet | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 50 50 |
47 | BAF312 2mg | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 50 50 |
48 | BAF312 4 mg tablet | 1件: Levonorgestrel Levonorgestrel | 1件: D00950
D00950
| 1件: PGR PGR 💬 | 5件: Breast cancer Breast cancer, Chemical carcinogenesis - receptor activation, Estrogen signaling pathway, Oocyte meiosis, Progesterone-mediated oocyte maturation 💬 | 1件: 13 13 |
49 | BAF312 4mg tablet | - | - | - | - | 1件: 50 50 |
50 | BAF312 5 mg tablet | - | - | - | - | 1件: 50 50 |
51 | BAF312 hemifumarate | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 2件: 13 13, 50 |
52 | BAF312A | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 13 13 |
53 | BAF312X | 1件: Siponimod Siponimod | 1件: D11460
D11460
| 2件: S1PR1 S1PR1, S1PR5 💬 | 3件: FoxO signaling pathway FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬 | 1件: 50 50 |
54 | Bafiertam | 1件: Monomethyl fumarate Monomethyl fumarate | 1件: D11492
D11492
| - | - | 1件: 13 13 |
55 | BAL | 1件: Dimercaprol Dimercaprol | 1件: D00167
D00167
| - | - | 5件: 49 49, 51, 84, 85, 299 |
56 | Balance | 1件: Olive oil Olive oil | 1件: D03311
D03311
| - | - | 8件: 6 6, 11, 13, 81, 113, 122, 149, 299 |
57 | Balance platform therapy | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
58 | Balance Training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
59 | Balance Training with Nintendo Wii Fit | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
60 | Ballon Pulmonary Angioplasty | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
61 | Balloon Pulmonary Angioplasty (BPA) | 1件: Bisphenol A Bisphenol A | - | - | - | 1件: 88 88 |
62 | Balsalazide | 1件: Balsalazide Balsalazide | 2件: D02715
D02715
,
D07488
| - | - | 1件: 97 97 |
63 | Balsalazide Disodium | 1件: Balsalazide Balsalazide | 2件: D02715
D02715
,
D07488
| - | - | 1件: 97 97 |
64 | Baminercept | 1件: Baminercept Baminercept | 1件: D08866
D08866
| 1件: LTB LTB 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 4件: 13 13, 46, 53, 97 |
65 | Baminercept alfa | 1件: Baminercept Baminercept | 1件: D08866
D08866
| 1件: LTB LTB 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 |
66 | Baminercept alfa (BG9924) | 1件: Baminercept Baminercept | 1件: D08866
D08866
| 1件: LTB LTB 💬 | 3件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 46 46 |
67 | Band | 1件: Albendazole Albendazole | 1件: D00134
D00134
| - | - | 2件: 6 6, 97 |
68 | Bardoxolone | 1件: Bardoxolone methyl Bardoxolone methyl | 1件: D09585
D09585
| - | - | 7件: 66 66, 67, 84, 85, 86, 218, 222 |
69 | Bardoxolone methyl | 1件: Bardoxolone methyl Bardoxolone methyl | 1件: D09585
D09585
| - | - | 7件: 66 66, 67, 84, 85, 86, 218, 222 |
70 | Bardoxolone methyl 10 mg | 1件: Bardoxolone methyl Bardoxolone methyl | 1件: D09585
D09585
| - | - | 1件: 67 67 |
71 | Bardoxolone methyl 15 mg | 1件: Bardoxolone methyl Bardoxolone methyl | 1件: D09585
D09585
| - | - | 1件: 67 67 |
72 | Bardoxolone methyl 20 mg | 1件: Bardoxolone methyl Bardoxolone methyl | 1件: D09585
D09585
| - | - | 1件: 67 67 |
73 | Bardoxolone methyl 5 mg | 1件: Bardoxolone methyl Bardoxolone methyl | 1件: D09585
D09585
| - | - | 1件: 67 67 |
74 | Bardoxolone methyl capsules | 1件: Bardoxolone methyl Bardoxolone methyl | 1件: D09585
D09585
| - | - | 4件: 66 66, 67, 86, 222 |
75 | Bardoxolone methyl oral capsule | 1件: Bardoxolone methyl Bardoxolone methyl | 1件: D09585
D09585
| - | - | 1件: 67 67 |
76 | BARDOXOLONE METHYL, CDDO-Me, CDDO-Methyl Ester, NSC 713200, Chemical Name: Oleana-1,9(11)-dien-28-oic acid, 2-cyano-3,12-dioxo-, methyl ester | 1件: Bardoxolone methyl Bardoxolone methyl | 1件: D09585
D09585
| - | - | 1件: 86 86 |
77 | Bardoxolone Metile | 1件: Bardoxolone methyl Bardoxolone methyl | 1件: D09585
D09585
| - | - | 1件: 67 67 |
78 | Baricinitib | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 49 49 |
79 | Baricitinib | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 13件: 41 41, 46, 49, 50, 51, 53, 93, 107, 162, 265, 268, 269, 325 |
80 | Baricitinib 2 MG | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 53 53 |
81 | Baricitinib 2 MG [Olumiant] | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 162 162 |
82 | Baricitinib Oral Tablet [Olumiant] | 1件: Baricitinib Baricitinib | 1件: D10308
D10308
| 2件: JAK1 JAK1, JAK2 💬 | 35件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
83 | Baricitinib treatment | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
84 | Baricitinib, olumiant® | 1件: Tofacitinib Tofacitinib | 1件: D09970
D09970
| 4件: JAK1 JAK1, JAK2, JAK3, TYK2 💬 | 37件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, Chemical carcinogenesis - receptor activation, Chemokine signaling pathway, Cholinergic synapse, Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Growth hormone synthesis, secretion and action, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Lipid and atherosclerosis, Measles, NOD-like receptor signaling pathway, Necroptosis, Non-small cell lung cancer, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Primary immunodeficiency, Prolactin signaling pathway, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
85 | Barium | 1件: Barium Barium | - | - | - | 3件: 2 2, 19, 98 |
86 | BARNASCAN | 1件: Fludeoxyglucose Fludeoxyglucose | 1件: D01843
D01843
| - | - | 1件: 88 88 |
87 | Bascial prescription plus or minus herbs depend on symptoms | - | - | - | - | 1件: 97 97 |
88 | Baseline disease modifying therapies (DMTs) | - | - | - | - | 1件: 13 13 |
89 | Baseline Treatment | 1件: Satralizumab Satralizumab | 1件: D11079
D11079
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 13 13 |
90 | Basiliximab | 1件: Basiliximab Basiliximab | 1件: D03058
D03058
| 1件: IL2RA IL2RA 💬 | 11件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Endocytosis, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, JAK-STAT signaling pathway, Measles, PI3K-Akt signaling pathway, Pathways in cancer, Th1 and Th2 cell differentiation, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 5件: 2 2, 50, 97, 222, 228 |
91 | Basimglurant | 1件: Basimglurant Basimglurant | 1件: D10864
D10864
| - | - | 1件: 158 158 |
92 | BASSADO | 1件: Doxycycline Doxycycline | 5件: D00307
D00307
,
D02129
,
D03903
,
D03904
,
D07876
| - | - | 1件: 23 23 |
93 | BASSADO 10CPS 100MG | 1件: Doxycycline Doxycycline | 5件: D00307
D00307
,
D02129
,
D03903
,
D03904
,
D07876
| - | - | 1件: 23 23 |
94 | BAT1406 | - | - | - | - | 1件: 271 271 |
95 | BAT1806 | 1件: Tocilizumab Tocilizumab | 1件: D02596
D02596
| 1件: IL6R IL6R 💬 | 12件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, JAK-STAT signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Th17 cell differentiation, Viral protein interaction with cytokine and cytokine receptor 💬 | 1件: 46 46 |
96 | BAT1806 injection | - | - | - | - | 1件: 46 46 |
97 | BAT4406F | - | - | - | - | 1件: 13 13 |
98 | Bavisant | 1件: Bavisant Bavisant | 1件: D09870
D09870
| 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
99 | Bavisant dihydrochloride monohydrate | 1件: Bavisant Bavisant | 1件: D09870
D09870
| 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
100 | BAVISANT HYDROCHLORIDE MONOHYDRATE | 1件: Bavisant Bavisant | 1件: D09870
D09870
| 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
101 | Bawei Shenqi Pill | 1件: Meloxicam Meloxicam | 1件: D00969
D00969
| 1件: PTGS2 PTGS2 💬 | 22件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 271 271 |
102 | BAX 111 | 1件: Antihemophilic factor, human recombinant Antihemophilic factor, human recombinant | 1件: D02958
D02958
| - | - | 1件: 288 288 |
103 | BAX111 | 1件: Antihemophilic factor, human recombinant Antihemophilic factor, human recombinant | 1件: D02958
D02958
| - | - | 1件: 288 288 |
104 | BAX930 | - | - | - | - | 1件: 64 64 |
105 | BAX930 - RECOMBINANT HUMAN ADAMTS13 | 1件: Apadamtase alfa Apadamtase alfa | - | - | - | 1件: 64 64 |
106 | BAX930 or SHP655 | 1件: Apadamtase alfa Apadamtase alfa | - | - | - | 1件: 64 64 |
107 | BAY 59-7939 | 1件: Acetylsalicylic acid Acetylsalicylic acid | 1件: D00109
D00109
| 2件: PTGS1 PTGS1, PTGS2 💬 | 23件: Alzheimer disease Alzheimer disease, Arachidonic acid metabolism, C-type lectin receptor signaling pathway, Chemical carcinogenesis - DNA adducts, Human cytomegalovirus infection, Human papillomavirus infection, IL-17 signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Metabolic pathways, MicroRNAs in cancer, NF-kappa B signaling pathway, Ovarian steroidogenesis, Oxytocin signaling pathway, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Platelet activation, Regulation of lipolysis in adipocytes, Retrograde endocannabinoid signaling, Serotonergic synapse, Small cell lung cancer, TNF signaling pathway, VEGF signaling pathway 💬 | 1件: 210 210 |
108 | BAY 63-2521 | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
109 | BAY 63-2521 0.06 % | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
110 | BAY 63-2521 0.3 % | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
111 | BAY 63-2521 coated tablets 0.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
112 | BAY 63-2521 coated tablets 1 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
113 | BAY 63-2521 coated tablets 1.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
114 | BAY 63-2521 coated tablets 2 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
115 | BAY 63-2521 coated tablets 2.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
116 | BAY 63-2521 IR coated tablet 1.0 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
117 | BAY 63-2521 IR coated tablet 1.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
118 | BAY 63-2521 IR coated tablet 2.0 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
119 | BAY 63-2521 IR coated tablet 2.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
120 | BAY 63-2521 IR tablet 0.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
121 | BAY 63-2521 IR tablet 1.0 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
122 | BAY 63-2521 IR tablet 1.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
123 | BAY 63-2521 IR tablet 2.0 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
124 | BAY 63-2521 IR tablet 2.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 88 88 |
125 | BAY 63-2521 IR tablets 0.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
126 | BAY 63-2521 IR tablets 1 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
127 | BAY 63-2521 IR tablets 1.0 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
128 | BAY 63-2521 IR tablets 1.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
129 | BAY 63-2521 IR tablets 2.0 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
130 | BAY 63-2521 IR tablets 2.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
131 | BAY 63-2521 Tablet | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
132 | BAY 63-2521 tablets 0.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
133 | BAY 63-2521 tablets 1 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
134 | BAY 63-2521 tablets 1.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
135 | BAY 63-2521 tablets 2 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
136 | BAY 63-2521 tablets 2.5 mg | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 2件: 86 86, 88 |
137 | BAY 79-4998 | 1件: Darifenacin Darifenacin | 2件: D01699
D01699
,
D03654
| 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 13 13 |
138 | BAY 85-8501 | - | - | - | - | 1件: 299 299 |
139 | BAY q 3939 | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
140 | Bay Q 6256 | 1件: Iloprost Iloprost | 1件: D02721
D02721
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
141 | BAY1237592 | - | - | - | - | 2件: 86 86, 88 |
142 | BAY63-2521 | 1件: Riociguat Riociguat | 1件: D09572
D09572
| 3件: GUCY1A1 GUCY1A1, GUCY1A2, GUCY1B1 💬 | 11件: Circadian entrainment Circadian entrainment, Gap junction, Long-term depression, Metabolic pathways, Oxytocin signaling pathway, Platelet activation, Purine metabolism, Renin secretion, Salivary secretion, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 3件: 51 51, 86, 299 |
143 | BAY85-8501 | - | - | - | - | 1件: 299 299 |
144 | BAY86-5046 | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
145 | BAY86-5046_Interferon-beta-1b | - | - | - | - | 1件: 13 13 |
146 | BAYQ3939 | 1件: Ciprofloxacin Ciprofloxacin | 2件: D00186
D00186
,
D02216
| - | - | 1件: 299 299 |
147 | Bazedoxifene | 1件: Bazedoxifene Bazedoxifene | - | - | - | 1件: 13 13 |
148 | Bazedoxifene Acetate | 1件: Bazedoxifene Bazedoxifene | - | - | - | 1件: 13 13 |
149 | BBP-418 | - | - | - | - | 1件: 113 113 |
150 | BBP-671 | - | - | - | - | 2件: 245 245, 246 |
151 | BBR 2778 | 1件: Pixantrone Pixantrone | 1件: D05522
D05522
| 2件: TOP2A TOP2A, TOP2B 💬 | 1件: Platinum drug resistance Platinum drug resistance 💬 | 2件: 11 11, 13 |
152 | BBT-401-1S | - | - | - | - | 1件: 97 97 |
153 | BBT-401-1S, Multiple doses | - | - | - | - | 1件: 97 97 |
154 | BBT-401-1S, Single dose | - | - | - | - | 1件: 97 97 |
155 | BBT-877, Multiple doses | - | - | - | - | 1件: 85 85 |
156 | BBT-877, Single dose | - | - | - | - | 1件: 85 85 |
157 | BCD-033 (interferon beta 1a) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
158 | BCD-054 180 mcg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
159 | BCD-054 240 mcg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
160 | BCD-055 | 1件: Infliximab Infliximab | 1件: D02598
D02598
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 2件: 46 46, 271 |
161 | BCD-063 | 1件: Glatiramer Glatiramer | 1件: D04318
D04318
| 20件: HLA-A HLA-A, HLA-B, HLA-C, HLA-DMA, HLA-DMB, HLA-DOA, HLA-DOB, HLA-DPA1, HLA-DPB1, HLA-DQA1, HLA-DQA2, HLA-DQB1, HLA-DRA, HLA-DRB1, HLA-DRB3, HLA-DRB4, HLA-DRB5, HLA-E, HLA-F, HLA-G 💬 | 32件: Allograft rejection Allograft rejection, Antigen processing and presentation, Asthma, Autoimmune thyroid disease, Cell adhesion molecules, Cellular senescence, Endocytosis, Epstein-Barr virus infection, Graft-versus-host disease, Hematopoietic cell lineage, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Inflammatory bowel disease, Influenza A, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Natural killer cell mediated cytotoxicity, Phagosome, Rheumatoid arthritis, Staphylococcus aureus infection, Systemic lupus erythematosus, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Viral carcinogenesis, Viral myocarditis 💬 | 1件: 13 13 |
162 | BCD-085 | - | - | - | - | 2件: 93 93, 271 |
163 | BCD-089 | 1件: Methotrexate Methotrexate | 2件: D00142
D00142
,
D02115
| 2件: DHFR DHFR, DHFR2 💬 | 5件: Antifolate resistance Antifolate resistance, Biosynthesis of cofactors, Folate biosynthesis, Metabolic pathways, One carbon pool by folate 💬 | 1件: 46 46 |
164 | BCD-089, 162 mg, s/c, q2w | - | - | - | - | 1件: 46 46 |
165 | BCD-089, 162 mg, s/c, qw | - | - | - | - | 1件: 46 46 |
166 | BCD-132 | - | - | - | - | 1件: 13 13 |
167 | BCD-132, 125 mg | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
168 | BCD-132, 500 mg | 1件: Teriflunomide Teriflunomide | 1件: D10172
D10172
| 1件: DHODH DHODH 💬 | 3件: Biosynthesis of cofactors Biosynthesis of cofactors, Metabolic pathways, Pyrimidine metabolism 💬 | 1件: 13 13 |
169 | BCD-148 | 1件: Eculizumab Eculizumab | 1件: D03940
D03940
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 1件: 62 62 |
170 | BCG | 1件: BCG vaccine BCG vaccine | 1件: D03063
D03063
| - | - | 1件: 299 299 |
171 | BCG TICE Vaccine | 1件: BCG vaccine BCG vaccine | 1件: D03063
D03063
| - | - | 1件: 299 299 |
172 | BCG20-0134 | 1件: Glycerin Glycerin | 1件: D00028
D00028
| - | - | 1件: 13 13 |
173 | BCX9930 | - | - | - | - | 3件: 62 62, 66, 222 |
174 | BCX9930 hydrochloride | 1件: Eculizumab Eculizumab | 1件: D03940
D03940
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 3件: 62 62, 66, 222 |
175 | BCX9930 monotherapy | - | - | - | - | 1件: 62 62 |
176 | BD | 1件: Bortezomib Bortezomib | 1件: D03150
D03150
| 1件: PSMB5 PSMB5 💬 | 8件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Huntington disease, Parkinson disease, Pathways of neurodegeneration - multiple diseases, Prion disease, Proteasome, Spinocerebellar ataxia 💬 | 2件: 28 28, 46 |
177 | BDMARD | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
178 | BDMARD treatment | - | - | - | - | 1件: 271 271 |
179 | BDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept) | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
180 | Beam | 1件: Tricyclazole Tricyclazole | - | - | - | 2件: 6 6, 51 |
181 | BEAM Regimen | - | - | - | - | 1件: 13 13 |
182 | Bean | 1件: Vitamin D Vitamin D | - | - | - | 1件: 96 96 |
183 | Beclometasone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
184 | Beclometasone dipropionate | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 2件: D00689
D00689
,
D07495
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 85 85, 97 |
185 | Beclomethasone dipropionate | 1件: Beclomethasone dipropionate Beclomethasone dipropionate | 2件: D00689
D00689
,
D07495
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 2件: 97 97, 98 |
186 | Beclomethasone diproprionate | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 97 97 |
187 | Bee venom | - | - | - | - | 1件: 6 6 |
188 | Bee venom pharmacopuncture | - | - | - | - | 1件: 70 70 |
189 | Beetainterferoni -1a | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
190 | Beetroot juice | - | - | - | - | 1件: 86 86 |
191 | BEFIRADOL | - | - | - | - | 1件: 6 6 |
192 | Befizal | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 |
193 | BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 |
194 | Begelomab | 1件: Clidinium Clidinium | - | - | - | 1件: 50 50 |
195 | Behavior and neuropsychometric evaluations | 1件: Somatotropin Somatotropin | 1件: D02691
D02691
| 1件: GHR GHR 💬 | 5件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Growth hormone synthesis, secretion and action, JAK-STAT signaling pathway, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway 💬 | 1件: 78 78 |
196 | Behavioral: 50 patients will have a Free Choice between Filgotinib and anti TNF | 1件: Filgotinib Filgotinib | 1件: D10871
D10871
| 1件: JAK1 JAK1 💬 | 27件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Leishmaniasis, Measles, NOD-like receptor signaling pathway, Necroptosis, Osteoclast differentiation, PD-L1 expression and PD-1 checkpoint pathway in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Signaling pathways regulating pluripotency of stem cells, Th1 and Th2 cell differentiation, Th17 cell differentiation, Toxoplasmosis, Tuberculosis, Viral carcinogenesis 💬 | 1件: 46 46 |
197 | Behavioral: 6 months weight resistance and balance program | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 13 13 |
198 | Behavioral: 60-minutes of steady state exercise | 1件: Caffeine Caffeine | 2件: D00528
D00528
,
D01453
| 11件: ADORA1 ADORA1, ADORA2A, PDE1B, PDE2A, PDE3A, PDE3B, PDE4A, PDE4B, PDE4C, PDE4D, PDE5A 💬 | 22件: Alcoholism Alcoholism, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Glucagon signaling pathway, Insulin signaling pathway, Metabolic pathways, Morphine addiction, Neuroactive ligand-receptor interaction, Olfactory transduction, Parathyroid hormone synthesis, secretion and action, Parkinson disease, Progesterone-mediated oocyte maturation, Purine metabolism, Rap1 signaling pathway, Regulation of lipolysis in adipocytes, Renin secretion, Sphingolipid signaling pathway, Taste transduction, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 265 265 |
199 | Behavioral: AbbVie Care 2.0 | 1件: Adalimumab Adalimumab | 1件: D02597
D02597
| 1件: TNF TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 4件: 46 46, 96, 97, 271 |
200 | Behavioral: Adherence counseling | 1件: Dimethyl fumarate Dimethyl fumarate | 1件: D03846
D03846
| 1件: KEAP1 KEAP1 💬 | 6件: Chemical carcinogenesis - reactive oxygen species Chemical carcinogenesis - reactive oxygen species, Fluid shear stress and atherosclerosis, Hepatocellular carcinoma, Parkinson disease, Pathways in cancer, Ubiquitin mediated proteolysis 💬 | 1件: 13 13 |
201 | Behavioral: Administration of probiotic (L. rhamnosus and L. acidophilus) | 1件: Lactobacillus acidophilus Lactobacillus acidophilus | 1件: D04349
D04349
| - | - | 1件: 97 97 |
202 | Behavioral: Aerobic exercise | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 299 299 |
203 | Behavioral: anal dilation | - | - | - | - | 1件: 291 291 |
204 | Behavioral: AO+VR | 1件: Carbon monoxide Carbon monoxide | 1件: D09706
D09706
| - | - | 1件: 149 149 |
205 | Behavioral: Assessment of cognition | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 |
206 | Behavioral: Assessment of depression | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 |
207 | Behavioral: Assessment of disability | 1件: Testosterone Testosterone | 6件: D00075
D00075
,
D00957
,
D00958
,
D00959
,
D06085
,
D06087
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 |
208 | Behavioral: Assessment of impact of MS on cognition | 1件: Testosterone Testosterone | 6件: D00075
D00075
,
D00957
,
D00958
,
D00959
,
D06085
,
D06087
| 1件: AR AR 💬 | 4件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Oocyte meiosis, Pathways in cancer, Prostate cancer 💬 | 1件: 13 13 |
209 | Behavioral: Assessment of motor and non-motors symptoms of PD Evaluation of hyper- and hypodopaminergic behaviors | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 |
210 | Behavioral: Assessment of quality of life | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 |
211 | Behavioral: Assessment of severity of ICD (impulse control disorders) | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 |
212 | Behavioral: Assessment of severity of Parkinson Disease | 1件: Pimavanserin Pimavanserin | - | - | - | 1件: 6 6 |
213 | Behavioral: Attention Control | 1件: Tropicamide Tropicamide | 1件: D00397
D00397
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 |
214 | Behavioral: Augmented Reality Multi-Modal Training | 1件: Sulpiride Sulpiride | 2件: D01226
D01226
,
D08549
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
215 | Behavioral: B-HIPE (Brief High Impact Preparatory Experience) | 1件: Topramezone Topramezone | - | - | - | 1件: 13 13 |
216 | Behavioral: Balance & Strengthening Exercises | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
217 | Behavioral: Balance exercise | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 299 299 |
218 | Behavioral: Balance Training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 2件: 6 6, 13 |
219 | Behavioral: BCI-FIT active querying | 1件: Sulpiride Sulpiride | 2件: D01226
D01226
,
D08549
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 3件: 2 2, 6, 17 |
220 | Behavioral: BCI-FIT adaptive signal modeling | 1件: Sulpiride Sulpiride | 2件: D01226
D01226
,
D08549
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 3件: 2 2, 6, 17 |
221 | Behavioral: BCI-FIT language modeling | 1件: Sulpiride Sulpiride | 2件: D01226
D01226
,
D08549
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 3件: 2 2, 6, 17 |
222 | Behavioral: BCI-FIT multi-modal access | 1件: Sulpiride Sulpiride | 2件: D01226
D01226
,
D08549
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 3件: 2 2, 6, 17 |
223 | Behavioral: Brisk walking and balance training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
224 | Behavioral: Building Better Caregivers Workshop | 1件: Tropicamide Tropicamide | 1件: D00397
D00397
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 6 6 |
225 | Behavioral: Cannabis questionnaire | 1件: Medical Cannabis Medical Cannabis | - | - | - | 2件: 46 46, 271 |
226 | Behavioral: CBT and sleep hygiene | 1件: Doxepin Doxepin | 2件: D00814
D00814
,
D07875
| 3件: HRH1 HRH1, SLC6A2, SLC6A4 💬 | 5件: Calcium signaling pathway Calcium signaling pathway, Inflammatory mediator regulation of TRP channels, Neuroactive ligand-receptor interaction, Serotonergic synapse, Synaptic vesicle cycle 💬 | 1件: 6 6 |
227 | Behavioral: CHDR Monitoring Remotely (MORE) | 1件: Methamidophos Methamidophos | - | - | - | 1件: 113 113 |
228 | Behavioral: Clinical characteristics of AMS patients | - | - | - | - | 1件: 17 17 |
229 | Behavioral: CO+VR | 1件: Carbon monoxide Carbon monoxide | 1件: D09706
D09706
| - | - | 1件: 149 149 |
230 | Behavioral: CO-OP treatment protocol | 1件: Carbon monoxide Carbon monoxide | 1件: D09706
D09706
| - | - | 1件: 6 6 |
231 | Behavioral: Cognitive and Behavioral experimental tasks | - | - | - | - | 2件: 6 6, 127 |
232 | Behavioral: Collaborative Care (CC) | 1件: Cholecalciferol Cholecalciferol | 1件: D00188
D00188
| 1件: VDR VDR 💬 | 5件: Chemical carcinogenesis - receptor activation Chemical carcinogenesis - receptor activation, Endocrine and other factor-regulated calcium reabsorption, Mineral absorption, Parathyroid hormone synthesis, secretion and action, Tuberculosis 💬 | 1件: 13 13 |
233 | Behavioral: colonic lavage | - | - | - | - | 1件: 291 291 |
234 | Behavioral: Combined balance and brisk walking training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
235 | Behavioral: Conservative Measures for Orthostatic Hypotension | 1件: Fludrocortisone Fludrocortisone | 2件: D00986
D00986
,
D07967
| 1件: NR3C2 NR3C2 💬 | 1件: Aldosterone-regulated sodium reabsorption Aldosterone-regulated sodium reabsorption 💬 | 2件: 6 6, 17 |
236 | Behavioral: conservative treatment | 1件: Lactulose Lactulose | 1件: D00352
D00352
| - | - | 1件: 291 291 |
237 | Behavioral: Control Group Typically Developing | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
238 | Behavioral: Dexterity | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
239 | Behavioral: Diet | 1件: Niacin Niacin | 1件: D00049
D00049
| - | - | 1件: 265 265 |
240 | Behavioral: Diet and water adjustment | 1件: Water Water | 1件: D00001
D00001
| - | - | 1件: 67 67 |
241 | Behavioral: Diet Counseling | 1件: Pyrimethamine Pyrimethamine | 1件: D00488
D00488
| - | - | 1件: 96 96 |
242 | Behavioral: Dietary Counseling | - | - | - | - | 1件: 46 46 |
243 | Behavioral: Dietary guidance | 1件: Omega-3 fatty acids Omega-3 fatty acids | - | - | - | 1件: 46 46 |
244 | Behavioral: Dietary Guidelines for Americans Diet | 1件: Olive oil Olive oil | 1件: D03311
D03311
| - | - | 1件: 13 13 |
245 | Behavioral: Dietary recommendations | - | - | - | - | 1件: 46 46 |
246 | Behavioral: Dual Task | 1件: Albendazole Albendazole | 1件: D00134
D00134
| - | - | 1件: 6 6 |
247 | Behavioral: Duchenne Muscular Dystrophy group with Deflazacort | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
248 | Behavioral: Duchenne Muscular Dystrophy group with Prednisone/Predisolone | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
249 | Behavioral: Duchenne Muscular Dystrophy group without Corticosteroids therapy | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
250 | Behavioral: Dyadic Psychological Support (DPS) | 1件: Pyrimethamine Pyrimethamine | 1件: D00488
D00488
| - | - | 1件: 96 96 |
251 | Behavioral: ECOCAPTURE | - | - | - | - | 2件: 6 6, 127 |
252 | Behavioral: Emotion Assessment | 1件: Albendazole Albendazole | 1件: D00134
D00134
| - | - | 1件: 6 6 |
253 | Behavioral: Environmental Decontamination | 1件: Mupirocin Mupirocin | 2件: D01076
D01076
,
D02195
| - | - | 1件: 299 299 |
254 | Behavioral: Exercise | 1件: Rasagiline Rasagiline | 3件: D02562
D02562
,
D08469
,
D10829
| 1件: MAOB MAOB 💬 | 14件: Alcoholism Alcoholism, Amphetamine addiction, Arginine and proline metabolism, Cocaine addiction, Dopaminergic synapse, Drug metabolism - cytochrome P450, Glycine, serine and threonine metabolism, Histidine metabolism, Metabolic pathways, Parkinson disease, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 3件: 6 6, 265, 299 |
255 | Behavioral: Exercise only | 1件: Sulpiride Sulpiride | 2件: D01226
D01226
,
D08549
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
256 | Behavioral: Exercise Training | 1件: Pioglitazone Pioglitazone | 2件: D00945
D00945
,
D08378
| 1件: PPARG PPARG 💬 | 11件: AMPK signaling pathway AMPK signaling pathway, Huntington disease, Lipid and atherosclerosis, Longevity regulating pathway, Non-alcoholic fatty liver disease, Osteoclast differentiation, PPAR signaling pathway, Pathways in cancer, Thermogenesis, Thyroid cancer, Transcriptional misregulation in cancer 💬 | 1件: 265 265 |
257 | Behavioral: exercise+multi-modal sensory feedback (MMSF) | 1件: Sulpiride Sulpiride | 2件: D01226
D01226
,
D08549
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
258 | Behavioral: Flexibility and postural exercise | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 299 299 |
259 | Behavioral: Flexibility and strengthening exercise | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
260 | Behavioral: Gait and balance | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
261 | Behavioral: gait and balance training program | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
262 | Behavioral: General healthy eating | 1件: Lysergic acid diethylamide Lysergic acid diethylamide | - | - | - | 1件: 271 271 |
263 | Behavioral: Healthy age-matched controls | - | - | - | - | 1件: 6 6 |
264 | Behavioral: heart health educational program | 1件: Folic acid Folic acid | 1件: D00070
D00070
| - | - | 1件: 49 49 |
265 | Behavioral: High/Low Sitosterol | 1件: beta-Sitosterol beta-Sitosterol | 1件: D08518
D08518
| - | - | 1件: 260 260 |
266 | Behavioral: Hypnosis | - | - | - | - | 1件: 96 96 |
267 | Behavioral: ICM_APATHY_TASKS | - | - | - | - | 2件: 6 6, 127 |
268 | Behavioral: Impact of four week coaching program on dietary habits | 1件: Topramezone Topramezone | - | - | - | 1件: 13 13 |
269 | Behavioral: In-home Exercise Training | 1件: Prednisone Prednisone | 1件: D00473
D00473
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 113 113 |
270 | Behavioral: Increased dietary intake of salmon or cod | 1件: Salmon, unspecified Salmon, unspecified | - | - | - | 1件: 97 97 |
271 | Behavioral: learning | 1件: Riboflavin Riboflavin | 3件: D00050
D00050
,
D01622
,
D01913
| - | - | 1件: 13 13 |
272 | Behavioral: Levodopa or acupuncture | 1件: Levodopa Levodopa | 1件: D00059
D00059
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
273 | Behavioral: Lifestyle | 1件: Valsartan Valsartan | 1件: D00400
D00400
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 58 58 |
274 | Behavioral: Low Starch Diet (LSD) | 1件: Lysergic acid diethylamide Lysergic acid diethylamide | - | - | - | 1件: 271 271 |
275 | Behavioral: Low-Impact Exercise Control | 1件: Topramezone Topramezone | - | - | - | 1件: 6 6 |
276 | Behavioral: Medical Marijuana | 1件: Medical Cannabis Medical Cannabis | - | - | - | 1件: 13 13 |
277 | Behavioral: meditation | 1件: Riboflavin Riboflavin | 3件: D00050
D00050
,
D01622
,
D01913
| - | - | 1件: 13 13 |
278 | Behavioral: Memory | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
279 | Behavioral: Modified Paleolithic Elimination diet | 1件: Olive oil Olive oil | 1件: D03311
D03311
| - | - | 1件: 13 13 |
280 | Behavioral: MOntreal Cognitive Assessment (MoCA) | - | - | - | - | 1件: 17 17 |
281 | Behavioral: Motivational Interviewing | 1件: Methamidophos Methamidophos | - | - | - | 1件: 13 13 |
282 | Behavioral: Neuro-psychological Assessment | 1件: Phenylalanine Phenylalanine | 1件: D00021
D00021
| - | - | 1件: 240 240 |
283 | Behavioral: Neurocognitive testing | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 19 19 |
284 | Behavioral: OM Meditation | - | - | - | - | 1件: 6 6 |
285 | Behavioral: Other Academic sham tutoring | 1件: Lovastatin Lovastatin | 1件: D00359
D00359
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 34 34 |
286 | Behavioral: Participant open-response writing | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
287 | Behavioral: Participant self-assessment surveys | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
288 | Behavioral: PAT sessions | 1件: Fenamole Fenamole | 1件: D04139
D04139
| - | - | 1件: 6 6 |
289 | Behavioral: Pelvic floor muscle exercise-based behavioral therapy | 1件: Solifenacin Solifenacin | 2件: D01269
D01269
,
D08522
| 1件: CHRM3 CHRM3 💬 | 11件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction 💬 | 1件: 6 6 |
290 | Behavioral: phenylalanine restricted diet | 1件: Phenylalanine Phenylalanine | 1件: D00021
D00021
| - | - | 1件: 240 240 |
291 | Behavioral: Phonation | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
292 | Behavioral: Physical Activity Together for PwMS and their CGs (PAT-MS) | 1件: Fenamole Fenamole | 1件: D04139
D04139
| - | - | 1件: 13 13 |
293 | Behavioral: physical exam and UPDRS part III assessment | 1件: Sargramostim Sargramostim | 1件: D05803
D05803
| 1件: CSF2RA CSF2RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 1件: 6 6 |
294 | Behavioral: Physical Therapy | 1件: Apomorphine Apomorphine | 2件: D02004
D02004
,
D07460
| 2件: DRD1 DRD1, DRD2 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
295 | Behavioral: PICC line placement | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 19 19 |
296 | Behavioral: pre DBS patients responding to the DBS-PS scale | 1件: Phosphatidyl serine Phosphatidyl serine | 1件: D04682
D04682
| - | - | 1件: 6 6 |
297 | Behavioral: Protein and calorie controlled diet | 1件: Ornithine Ornithine | 1件: D08302
D08302
| - | - | 1件: 251 251 |
298 | Behavioral: quality of life assessment | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 81 81 |
299 | Behavioral: Questionnaire | - | - | - | - | 1件: 46 46 |
300 | Behavioral: Questionnaires | 1件: Melphalan Melphalan | 1件: D00369
D00369
| - | - | 2件: 28 28, 49 |
301 | Behavioral: reading tutoring intervention | 1件: Lovastatin Lovastatin | 1件: D00359
D00359
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 34 34 |
302 | Behavioral: Regular exercise | - | - | - | - | 1件: 113 113 |
303 | Behavioral: Resistance exercise | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 299 299 |
304 | Behavioral: Resistance Training | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
305 | Behavioral: respiratory and exercise therapy | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 1件: 88 88 |
306 | Behavioral: respiratory and exercise therapy with supplemental oxygen | 1件: Oxygen Oxygen | 1件: D00003
D00003
| - | - | 1件: 88 88 |
307 | Behavioral: Rest | 1件: Albendazole Albendazole | 1件: D00134
D00134
| - | - | 1件: 6 6 |
308 | Behavioral: Restricted phenylalanine diet | 1件: Phenylalanine Phenylalanine | 1件: D00021
D00021
| - | - | 1件: 240 240 |
309 | Behavioral: Role of dopamine | 1件: Dopamine Dopamine | 2件: D00633
D00633
,
D07870
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
310 | Behavioral: self massage | 1件: Riboflavin Riboflavin | 3件: D00050
D00050
,
D01622
,
D01913
| - | - | 1件: 13 13 |
311 | Behavioral: Single Task | 1件: Albendazole Albendazole | 1件: D00134
D00134
| - | - | 1件: 6 6 |
312 | Behavioral: SIT Scoring | 1件: Barium Barium | - | - | - | 1件: 2 2 |
313 | Behavioral: six-foods elimination diet | 1件: Budesonide Budesonide | 1件: D00246
D00246
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 98 98 |
314 | Behavioral: Sleep quality and physical activity | 1件: Nicotine Nicotine | 3件: D03365
D03365
,
D05156
,
D05157
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 7件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases 💬 | 1件: 13 13 |
315 | Behavioral: Smoking | 1件: Nicotine Nicotine | 3件: D03365
D03365
,
D05156
,
D05157
| 16件: CHRNA1 CHRNA1, CHRNA10, CHRNA2, CHRNA3, CHRNA4, CHRNA5, CHRNA6, CHRNA7, CHRNA9, CHRNB1, CHRNB2, CHRNB3, CHRNB4, CHRND, CHRNE, CHRNG 💬 | 7件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Neuroactive ligand-receptor interaction, Nicotine addiction, Pathways of neurodegeneration - multiple diseases 💬 | 1件: 13 13 |
316 | Behavioral: smoking and alcohol assumption | 1件: Ethanol Ethanol | 4件: D00068
D00068
,
D02798
,
D04855
,
D06542
| - | - | 1件: 298 298 |
317 | Behavioral: Speech Intelligibility Test (SIT) | 1件: Barium Barium | - | - | - | 1件: 2 2 |
318 | Behavioral: Step Tracking | 1件: Water Water | 1件: D00001
D00001
| - | - | 1件: 13 13 |
319 | Behavioral: steps per day | - | - | - | - | 1件: 6 6 |
320 | Behavioral: Strength training | 1件: Topramezone Topramezone | - | - | - | 1件: 6 6 |
321 | Behavioral: stretching | 1件: Carnosine Carnosine | - | - | - | 1件: 6 6 |
322 | Behavioral: Tai Chi | 1件: Topramezone Topramezone | - | - | - | 1件: 6 6 |
323 | Behavioral: Telephone-based Cognitive Behavioral Therapy | 1件: Modafinil Modafinil | 1件: D01832
D01832
| - | - | 1件: 13 13 |
324 | Behavioral: The M.D. Anderson Symptom Inventory (MDASI) | 1件: Siltuximab Siltuximab | 1件: D09669
D09669
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 28 28 |
325 | Behavioral: Time Restricted Olive Oil Based (TROO) Ketogenic Diet | 1件: Olive oil Olive oil | 1件: D03311
D03311
| - | - | 1件: 13 13 |
326 | Behavioral: TIP / IMPACT Plus Care Coordination | 1件: Topramezone Topramezone | - | - | - | 3件: 46 46, 96, 97 |
327 | Behavioral: Tobacco Treatment Specialist (TTS) intervention | 1件: Tobacco leaf Tobacco leaf | - | - | - | 1件: 299 299 |
328 | Behavioral: Traditional Multi-Modal Training | 1件: Sulpiride Sulpiride | 2件: D01226
D01226
,
D08549
| 1件: DRD2 DRD2 💬 | 8件: Alcoholism Alcoholism, Cocaine addiction, Dopaminergic synapse, Gap junction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
329 | Behavioral: Unsupervised exercise | - | - | - | - | 1件: 299 299 |
330 | Behavioral: Upper limb exercise | 1件: Isoxaflutole Isoxaflutole | - | - | - | 1件: 6 6 |
331 | Behavioral: Water Tracking | 1件: Water Water | 1件: D00001
D00001
| - | - | 1件: 13 13 |
332 | Behavioral: Withings Blood Pressure Monitor | 1件: Methamidophos Methamidophos | - | - | - | 1件: 113 113 |
333 | Behavioral: Withings Body+ scale | 1件: Methamidophos Methamidophos | - | - | - | 1件: 113 113 |
334 | Behavioral: Withings Steel HR | 1件: Methamidophos Methamidophos | - | - | - | 1件: 113 113 |
335 | Belantamab mafodotin | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
336 | Belantamab mafodotin 1.9 mg/kg (8 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
337 | Belantamab mafodotin 1.9mg/kg or 2.5mg/kg every 4 weeks, 6 weeks or 8 weeks as determined by Part 1 recommended dosages | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
338 | Belantamab mafodotin 2.5 mg/kg (4 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
339 | Belantamab mafodotin 2.5 mg/kg (6 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
340 | Belantamab mafodotin 2.5 mg/kg (8 weeks) | 1件: Belantamab mafodotin Belantamab mafodotin | 1件: D11595
D11595
| 10件: TNFRSF17 TNFRSF17, TUBB, TUBB1, TUBB2A, TUBB2B, TUBB3, TUBB4A, TUBB4B, TUBB6, TUBB8 💬 | 12件: Alzheimer disease Alzheimer disease, Amyotrophic lateral sclerosis, Cytokine-cytokine receptor interaction, Gap junction, Huntington disease, Intestinal immune network for IgA production, Parkinson disease, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Phagosome, Prion disease, Salmonella infection 💬 | 1件: 28 28 |
341 | Belatacept | 1件: Abatacept Abatacept | 1件: D03203
D03203
| 2件: CD80 CD80, CD86 💬 | 12件: Allograft rejection Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Graft-versus-host disease, Intestinal immune network for IgA production, Kaposi sarcoma-associated herpesvirus infection, Rheumatoid arthritis, Systemic lupus erythematosus, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis 💬 | 1件: 46 46 |
342 | Belcesiran | - | - | - | - | 1件: 231 231 |
343 | BELIMUMAB | 1件: Azathioprine Azathioprine | 2件: D00238
D00238
,
D03033
| - | - | 12件: 11 11, 13, 43, 44, 46, 49, 51, 53, 66, 222, 296, 300 |
344 | Belimumab 1 mg/kg | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 46 46, 49 |
345 | Belimumab 10 mg | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 222 222 |
346 | Belimumab 10 mg/kg | 1件: Azathioprine Azathioprine | 2件: D00238
D00238
,
D03033
| - | - | 3件: 43 43, 46, 49 |
347 | Belimumab 10 mg/kg plus standard therapy | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
348 | Belimumab 100 mg SC | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
349 | Belimumab 10mg/kg | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
350 | Belimumab 200 mg SC | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
351 | Belimumab 200 mg/mL | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
352 | Belimumab 4 mg/kg | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 46 46, 49 |
353 | Belimumab autoinjector | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
354 | Belimumab for IV | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
355 | Belimumab for SC | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
356 | Belimumab Injection | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
357 | Belimumab Injection [Benlysta] | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
358 | Belimumab or benlysta | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 49 49 |
359 | Belimumab plus Early Vaccination | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
360 | Belimumab plus Late Vaccination | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
361 | Beloranib | 1件: Beloranib Beloranib | - | - | - | 1件: 193 193 |
362 | Belumosudil | 1件: Belumosudil Belumosudil | 1件: D11815
D11815
| 1件: ROCK2 ROCK2 💬 | 21件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 |
363 | Belumosudil (KD025) | 1件: Belumosudil Belumosudil | 1件: D11815
D11815
| 1件: ROCK2 ROCK2 💬 | 21件: Axon guidance Axon guidance, Chemokine signaling pathway, Focal adhesion, Human cytomegalovirus infection, Leukocyte transendothelial migration, Lipid and atherosclerosis, Oxytocin signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Platelet activation, Proteoglycans in cancer, Regulation of actin cytoskeleton, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Tight junction, Vascular smooth muscle contraction, Wnt signaling pathway, Yersinia infection, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 51 51 |
364 | BEN-2001 | - | - | - | - | 1件: 6 6 |
365 | Benazepril | 1件: Benazepril Benazepril | 2件: D00620
D00620
,
D07499
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 4件: 49 49, 57, 218, 224 |
366 | Benazepril hydrochloride 10 milligram (mg) Tab | 1件: Benazepril Benazepril | 2件: D00620
D00620
,
D07499
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 218 218 |
367 | Benazepril Hydrochloride Tablets | 1件: Benazepril Benazepril | 2件: D00620
D00620
,
D07499
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 224 224 |
368 | Benazepril Pill | 1件: Benazepril Benazepril | 2件: D00620
D00620
,
D07499
| 1件: ACE ACE 💬 | 6件: Chagas disease Chagas disease, Coronavirus disease - COVID-19, Diabetic cardiomyopathy, Hypertrophic cardiomyopathy, Renin secretion, Renin-angiotensin system 💬 | 1件: 49 49 |
369 | Benazepril, Valsartan and Fluvastatin | 1件: Valsartan Valsartan | 1件: D00400
D00400
| 1件: AGTR1 AGTR1 💬 | 16件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease - COVID-19, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬 | 1件: 218 218 |
370 | Bendamustine | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 2件: 28 28, 61 |
371 | BENDAMUSTINE HYDROCHLORIDE | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 61 61 |
372 | Bendamustine, Rituximab | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 61 61 |
373 | BENDROFLUMETHIAZIDE | 1件: Amlodipine Amlodipine | 3件: D00615
D00615
,
D02914
,
D07450
| 4件: CACNA1C CACNA1C, CACNA1D, CACNA1F, CACNA1S 💬 | 37件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Alzheimer disease, Amphetamine addiction, Arrhythmogenic right ventricular cardiomyopathy, Calcium signaling pathway, Carbohydrate digestion and absorption, Cardiac muscle contraction, Cellular senescence, Chemical carcinogenesis - receptor activation, Cholinergic synapse, Circadian entrainment, Cortisol synthesis and secretion, Cushing syndrome, Dilated cardiomyopathy, Dopaminergic synapse, GABAergic synapse, Glutamatergic synapse, GnRH secretion, GnRH signaling pathway, Growth hormone synthesis, secretion and action, Hypertrophic cardiomyopathy, Insulin secretion, Long-term potentiation, MAPK signaling pathway, Oxytocin signaling pathway, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, Retrograde endocannabinoid signaling, Serotonergic synapse, Taste transduction, Tight junction, Type II diabetes mellitus, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 67 67 |
374 | Benepali | 1件: Etanercept Etanercept | 1件: D00742
D00742
| 2件: LTA LTA, TNF 💬 | 67件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Adipocytokine signaling pathway, African trypanosomiasis, Alcoholic liver disease, Allograft rejection, Alzheimer disease, Amoebiasis, Amyotrophic lateral sclerosis, Antifolate resistance, Antigen processing and presentation, Apoptosis, Asthma, C-type lectin receptor signaling pathway, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Dilated cardiomyopathy, Epstein-Barr virus infection, Fc epsilon RI signaling pathway, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Human papillomavirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Legionellosis, Leishmaniasis, Lipid and atherosclerosis, MAPK signaling pathway, Malaria, NF-kappa B signaling pathway, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathogenic Escherichia coli infection, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Proteoglycans in cancer, RIG-I-like receptor signaling pathway, Rheumatoid arthritis, Salmonella infection, Shigellosis, Sphingolipid signaling pathway, Systemic lupus erythematosus, T cell receptor signaling pathway, TGF-beta signaling pathway, TNF signaling pathway, Toll-like receptor signaling pathway, Toxoplasmosis, Tuberculosis, Type I diabetes mellitus, Type II diabetes mellitus, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection, mTOR signaling pathway 💬 | 1件: 46 46 |
375 | Benerva | 1件: Biotin Biotin | 1件: D00029
D00029
| - | - | 1件: 8 8 |
376 | Benlysta | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 5件: 43 43, 49, 53, 66, 222 |
377 | Benlysta (belimumab) | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 4件: 11 11, 49, 53, 222 |
378 | BENLYSTA - 120 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) 120 MG 1 FLACONCINO | 1件: Rituximab Rituximab | 1件: D02994
D02994
| 1件: MS4A1 MS4A1 💬 | 1件: Hematopoietic cell lineage Hematopoietic cell lineage 💬 | 1件: 53 53 |
379 | Benlysta 400 mg powder for concentrate for solution for infusion | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 43 43, 49 |
380 | Benlysta 400 mg powder for concentrate for solution for infusions | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
381 | Benlysta 400mg polvere per concentrato per soluzione per infusione | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 43 43 |
382 | BENLYSTA? (belimumab) | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
383 | Benlysta® | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 2件: 49 49, 222 |
384 | BENLYSTA® (belimumab) | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 3件: 11 11, 66, 222 |
385 | BENLYSTA™ (belimumab) | 1件: Belimumab Belimumab | 1件: D03068
D03068
| 1件: TNFSF13B TNFSF13B 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬 | 1件: 49 49 |
386 | Benralizumab | 1件: Benralizumab Benralizumab | 1件: D09874
D09874
| 1件: IL5RA IL5RA 💬 | 4件: Cytokine-cytokine receptor interaction Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, JAK-STAT signaling pathway, Pathways in cancer 💬 | 5件: 44 44, 45, 98, 162, 299 |
387 | BENSERAZIDE | 1件: Levodopa Levodopa | 1件: D00059
D00059
| 5件: DRD1 DRD1, DRD2, DRD3, DRD4, DRD5 💬 | 11件: Alcoholism Alcoholism, Amphetamine addiction, Calcium signaling pathway, Cocaine addiction, Dopaminergic synapse, Gap junction, Morphine addiction, Neuroactive ligand-receptor interaction, Parkinson disease, Rap1 signaling pathway, cAMP signaling pathway 💬 | 1件: 6 6 |
388 | BENSERAZIDE HYDROCHLORIDE | 1件: Carbidopa Carbidopa | 1件: D00558
D00558
| 1件: DDC DDC 💬 | 9件: Alcoholism Alcoholism, Amphetamine addiction, Cocaine addiction, Dopaminergic synapse, Metabolic pathways, Phenylalanine metabolism, Serotonergic synapse, Tryptophan metabolism, Tyrosine metabolism 💬 | 1件: 6 6 |
389 | Benzbromaron | 1件: Albendazole Albendazole | 1件: D00134
D00134
| - | - | 1件: 86 86 |
390 | Benzbromaron AL | 1件: Albendazole Albendazole | 1件: D00134
D00134
| - | - | 1件: 86 86 |
391 | BENZBROMARONE | 1件: Benzbromarone Benzbromarone | 1件: D01056
D01056
| - | - | 1件: 86 86 |
392 | Benzimidazole | 1件: Omeprazole Omeprazole | 4件: D00455
D00455
,
D01207
,
D05259
,
D05261
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 46 46 |
393 | Benzimidazole,5-methoxy-2-[[(4-methoxy- 3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Omeprazole Omeprazole | 4件: D00455
D00455
,
D01207
,
D05259
,
D05261
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 46 46 |
394 | Benzimidazole,5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1 H-benzimidazole | 1件: Omeprazole Omeprazole | 4件: D00455
D00455
,
D01207
,
D05259
,
D05261
| 2件: ATP4A ATP4A, ATP4B 💬 | 4件: Collecting duct acid secretion Collecting duct acid secretion, Gastric acid secretion, Metabolic pathways, Oxidative phosphorylation 💬 | 1件: 46 46 |
395 | Benznidazole | 1件: Benznidazole Benznidazole | 1件: D02489
D02489
| - | - | 1件: 65 65 |
396 | Benzofuran | 1件: Benzofuran Benzofuran | - | - | - | 1件: 6 6 |
397 | Benzoic acid | 1件: Benzoic acid Benzoic acid | 1件: D00038
D00038
| - | - | 1件: 51 51 |
398 | Benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala) | 1件: Tyrosine Tyrosine | 1件: D00022
D00022
| - | - | 1件: 298 298 |
399 | Bepranemab | - | - | - | - | 1件: 5 5 |
400 | Berachin | 1件: Clenbuterol Clenbuterol | 1件: D07713
D07713
| 1件: ADRB2 ADRB2 💬 | 9件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 6 6 |
401 | Beraprost | 1件: Beraprost Beraprost | 1件: D02720
D02720
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
402 | Beraprost Sodium | 1件: Sildenafil Sildenafil | 2件: D02229
D02229
,
D08514
| 1件: PDE5A PDE5A 💬 | 3件: Metabolic pathways Metabolic pathways, Purine metabolism, cGMP-PKG signaling pathway 💬 | 1件: 86 86 |
403 | Beraprost Sodium 314d Modified Release Tablets | 1件: Beraprost Beraprost | 1件: D02720
D02720
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
404 | Beraprost Sodium Modified Release | 1件: Beraprost Beraprost | 1件: D02720
D02720
| 1件: PTGIR PTGIR 💬 | 3件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction, Platelet activation, Vascular smooth muscle contraction 💬 | 1件: 86 86 |
405 | Berberine | 1件: Berberine Berberine | - | - | - | 2件: 97 97, 265 |
406 | Berberine Chloride | 1件: Berberine Berberine | - | - | - | 1件: 97 97 |
407 | BERMEKIMAB | 1件: Bermekimab Bermekimab | 1件: D11253
D11253
| 1件: IL1A IL1A 💬 | 21件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Alzheimer disease, Cellular senescence, Cytokine-cytokine receptor interaction, Fluid shear stress and atherosclerosis, Graft-versus-host disease, Hematopoietic cell lineage, Inflammatory bowel disease, Influenza A, Leishmaniasis, MAPK signaling pathway, Measles, Necroptosis, Non-alcoholic fatty liver disease, Osteoclast differentiation, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Tuberculosis, Type I diabetes mellitus 💬 | 1件: 51 51 |
408 | Bertilimumab | - | - | - | - | 2件: 97 97, 162 |
409 | Best Available Therapy (BAT) | - | - | - | - | 1件: 13 13 |
410 | Best Medical Treatment | - | - | - | - | 1件: 6 6 |
411 | Best médical treatment | - | - | - | - | 1件: 6 6 |
412 | Best Supportive Care (BSC) | 1件: Siltuximab Siltuximab | 1件: D09669
D09669
| 1件: IL6 IL6 💬 | 51件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, African trypanosomiasis, Alcoholic liver disease, Alzheimer disease, Amoebiasis, Antifolate resistance, C-type lectin receptor signaling pathway, Cellular senescence, Chagas disease, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Cytosolic DNA-sensing pathway, EGFR tyrosine kinase inhibitor resistance, Epstein-Barr virus infection, FoxO signaling pathway, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Hepatitis B, Herpes simplex virus 1 infection, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Hypertrophic cardiomyopathy, IL-17 signaling pathway, Inflammatory bowel disease, Influenza A, Insulin resistance, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Legionellosis, Lipid and atherosclerosis, Malaria, Measles, NOD-like receptor signaling pathway, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathogenic Escherichia coli infection, Pathways in cancer, Pathways of neurodegeneration - multiple diseases, Pertussis, Prion disease, Rheumatoid arthritis, Salmonella infection, TNF signaling pathway, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Tuberculosis, Viral protein interaction with cytokine and cytokine receptor, Yersinia infection 💬 | 1件: 331 331 |
413 | Beta carotene | 1件: Beta carotene Beta carotene | 1件: D03101
D03101
| - | - | 1件: 96 96 |
414 | Beta carotene from Dunaliella algae | 1件: Beta carotene Beta carotene | 1件: D03101
D03101
| - | - | 1件: 96 96 |
415 | Beta Hydroxybutyrate | - | - | - | - | 1件: 2 2 |
416 | Beta-1,3/1,6-D-Glucan | - | - | - | - | 1件: 97 97 |
417 | Beta-1b interferoni | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
418 | Beta-Adrenergic cocktail | 1件: Pilocarpine Pilocarpine | 3件: D00525
D00525
,
D02200
,
D05478
| 2件: CHRM2 CHRM2, CHRM3 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 299 299 |
419 | Beta-Alanine | 1件: Alanine Alanine | 1件: D00012
D00012
| - | - | 1件: 13 13 |
420 | Beta-alanine supplementation | 1件: Alanine Alanine | 1件: D00012
D00012
| - | - | 1件: 13 13 |
421 | Beta-Carotene | 1件: Beta carotene Beta carotene | 1件: D03101
D03101
| - | - | 1件: 13 13 |
422 | Beta-cyclodextrin | 1件: Betadex Betadex | 1件: D02401
D02401
| - | - | 1件: 19 19 |
423 | Beta-Galactosidase | 1件: Lysine Lysine | 1件: D02304
D02304
| - | - | 1件: 19 19 |
424 | Beta-hydroxybuturate esters | - | - | - | - | 1件: 256 256 |
425 | Beta-Interferon | 1件: Atorvastatin Atorvastatin | 3件: D00258
D00258
,
D00887
,
D07474
| 1件: HMGCR HMGCR 💬 | 4件: AMPK signaling pathway AMPK signaling pathway, Bile secretion, Metabolic pathways, Terpenoid backbone biosynthesis 💬 | 1件: 13 13 |
426 | Beta-Mercaptoethylamine | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
427 | Beta-mercaptoethylamine Hydrochloride & 2-aminoethanethiol Hydrochloride | 1件: Cysteamine Cysteamine | 2件: D03634
D03634
,
D03635
| - | - | 1件: 19 19 |
428 | BETACAROTENE | 1件: Beta carotene Beta carotene | 1件: D03101
D03101
| - | - | 1件: 13 13 |
429 | BETACONNECT | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
430 | Betaconnect auto-injector | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
431 | BETACONNECT auto-injector. | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
432 | Betaconnect Autoinjector | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
433 | BETACONNECT device | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
434 | BETAFERON | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
435 | BETAFERON - 15 FLACONCINI 0.25 MG + 15 FLACONCINI 2 ML | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
436 | BETAFERON 250 mcg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
437 | Betaferon 250 microgram/ml | 1件: Human immunoglobulin G Human immunoglobulin G | - | - | - | 1件: 13 13 |
438 | Betaferon 250 microgram/ml, powder and solvent for solution for injection | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
439 | Betaferon 250 microgram/mL, powder and solvent for solution for injection. | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
440 | Betaferon 250 microgramos | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
441 | Betaferon 250mcg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
442 | Betaferon 250µg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
443 | BETAFERON 500 mcg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
444 | Betaferon 500 µg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
445 | Betaferon 500mcg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
446 | Betaferon 500µg | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
447 | BETAFERON SC 15F 0,25MG 15SIR | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
448 | BETAFERON*15CONFEZ 0,25MG/ML+ | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
449 | Betaferon, BAY86-5046 | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
450 | Betaferon/Betaseron | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
451 | Betaferon® | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
452 | BETAFERON® (interferon beta-1b) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
453 | Betaine | 1件: Betaine Betaine | 1件: D07523
D07523
| - | - | 2件: 201 201, 337 |
454 | Betaloc ZOK 100, 95 mg | 1件: Metoprolol Metoprolol | 3件: D00601
D00601
,
D02358
,
D05011
| 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 113 113 |
455 | Betaloc ZOK 25, 23,75 mg | 1件: Metoprolol Metoprolol | 3件: D00601
D00601
,
D02358
,
D05011
| 1件: ADRB1 ADRB1 💬 | 11件: Adrenergic signaling in cardiomyocytes Adrenergic signaling in cardiomyocytes, Calcium signaling pathway, Chemical carcinogenesis - receptor activation, Dilated cardiomyopathy, Gap junction, Neuroactive ligand-receptor interaction, Regulation of lipolysis in adipocytes, Renin secretion, Salivary secretion, cAMP signaling pathway, cGMP-PKG signaling pathway 💬 | 1件: 113 113 |
456 | Betamethasone | 1件: Betamethasone Betamethasone | 7件: D00244
D00244
,
D00972
,
D01357
,
D01402
,
D01637
,
D02032
,
D02286
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 7件: 2 2, 28, 46, 83, 90, 96, 235 |
457 | BETAMETHASONE ACIBUTATE | 1件: Betamethasone Betamethasone | 7件: D00244
D00244
,
D00972
,
D01357
,
D01402
,
D01637
,
D02032
,
D02286
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 46 46 |
458 | Betamethasone sodium phosphate/betamethasone acetate (Celestone® Soluspan®), 30 mg IM once a day for four days | 1件: Betamethasone Betamethasone | 7件: D00244
D00244
,
D00972
,
D01357
,
D01402
,
D01637
,
D02032
,
D02286
| 1件: NR3C1 NR3C1 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 2 2 |
459 | Betaquik MCT supplement | 1件: Medium-chain triglycerides Medium-chain triglycerides | - | - | - | 1件: 6 6 |
460 | Betaseron | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
461 | Betaseron (Interferon beta-1b, BAY86-5046) | 1件: Interferon beta-1b Interferon beta-1b | 1件: D00746
D00746
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
462 | Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
463 | Bethanechol | 1件: Bethanechol Bethanechol | 1件: D01000
D01000
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 1件: 98 98 |
464 | Bethkis | 1件: Aztreonam Aztreonam | 2件: D00240
D00240
,
D06558
| - | - | 1件: 299 299 |
465 | Better | 1件: Tropicamide Tropicamide | 1件: D00397
D00397
| 5件: CHRM1 CHRM1, CHRM2, CHRM3, CHRM4, CHRM5 💬 | 13件: Alzheimer disease Alzheimer disease, Calcium signaling pathway, Cholinergic synapse, Gastric acid secretion, Insulin secretion, Neuroactive ligand-receptor interaction, PI3K-Akt signaling pathway, Pancreatic secretion, Pathways of neurodegeneration - multiple diseases, Regulation of actin cytoskeleton, Salivary secretion, Taste transduction, cAMP signaling pathway 💬 | 2件: 6 6, 13 |
466 | Bevacizumab | 1件: Bevacizumab Bevacizumab | 1件: D06409
D06409
| 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 9件: 13 13, 34, 85, 86, 87, 89, 227, 280, 331 |
467 | Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec) | 1件: Bevacizumab Bevacizumab | 1件: D06409
D06409
| 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 1件: 87 87 |
468 | Bevacizumab (Genitical Recombination) | 1件: Bevacizumab Bevacizumab | 1件: D06409
D06409
| 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 1件: 34 34 |
469 | BEVACIZUMAB ZIRCONIUM ZR-89 | 1件: Bevacizumab Bevacizumab | 1件: D06409
D06409
| 1件: VEGFA VEGFA 💬 | 24件: AGE-RAGE signaling pathway in diabetic complications AGE-RAGE signaling pathway in diabetic complications, Bladder cancer, Calcium signaling pathway, Chemical carcinogenesis - reactive oxygen species, Chemical carcinogenesis - receptor activation, EGFR tyrosine kinase inhibitor resistance, Fluid shear stress and atherosclerosis, Focal adhesion, HIF-1 signaling pathway, Human cytomegalovirus infection, Human papillomavirus infection, Kaposi sarcoma-associated herpesvirus infection, MAPK signaling pathway, MicroRNAs in cancer, PI3K-Akt signaling pathway, Pancreatic cancer, Pathways in cancer, Proteoglycans in cancer, Rap1 signaling pathway, Ras signaling pathway, Relaxin signaling pathway, Renal cell carcinoma, Rheumatoid arthritis, VEGF signaling pathway 💬 | 1件: 34 34 |
470 | Bevacuzimab spray | - | - | - | - | 1件: 227 227 |
471 | Bevantolol | 1件: Bevantolol Bevantolol | - | - | - | 1件: 8 8 |
472 | BEVANTOLOL HYDROCHLORIDE | 1件: Bevantolol Bevantolol | - | - | - | 1件: 8 8 |
473 | Bexarotene | 1件: Bexarotene Bexarotene | 1件: D03106
D03106
| 3件: RXRA RXRA, RXRB, RXRG 💬 | 17件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Bile secretion, Chemical carcinogenesis - receptor activation, Gastric cancer, Hepatitis C, Lipid and atherosclerosis, Non-alcoholic fatty liver disease, Non-small cell lung cancer, PI3K-Akt signaling pathway, PPAR signaling pathway, Parathyroid hormone synthesis, secretion and action, Pathways in cancer, Small cell lung cancer, Th17 cell differentiation, Thyroid cancer, Thyroid hormone signaling pathway, Transcriptional misregulation in cancer 💬 | 2件: 13 13, 75 |
474 | Bexsero | 1件: Eculizumab Eculizumab | 1件: D03940
D03940
| 1件: C5 C5 💬 | 10件: Alcoholic liver disease Alcoholic liver disease, Complement and coagulation cascades, Coronavirus disease - COVID-19, Herpes simplex virus 1 infection, Neuroactive ligand-receptor interaction, Neutrophil extracellular trap formation, Pertussis, Prion disease, Staphylococcus aureus infection, Systemic lupus erythematosus 💬 | 6件: 11 11, 13, 61, 62, 66, 222 |
475 | BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA P | 1件: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine | - | - | - | 1件: 62 62 |
476 | BEXSERO - SOSPENSIONE INIETTABILE - USO INTRAMUSCOLARE - SIRINGA PRERIEMPITA (VETRO) - 0.5ML - 1 SIRINGA PRERIEMPITA CON AGO | 1件: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine | - | - | - | 1件: 66 66 |
477 | BEXSERO – Sospensione iniettabile – Siringa preriempita | 1件: Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine | - | - | - | 2件: 61 61, 62 |
478 | Bezafibrat | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
479 | Bezafibrat Genericon retard 400 mg | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
480 | Bezafibrate | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 7件: 20 20, 93, 94, 160, 296, 316, 324 |
481 | Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 94 94 |
482 | Bezafibrate (drug) | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 316 316 |
483 | Bezafibrate (INN 3968) | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 324 324 |
484 | Bezafibrate 100 MG | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
485 | Bezafibrate 200 MG | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
486 | Bezafibrate 200 MG Oral Tablet | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
487 | Bezafibrate 400 MG | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
488 | Bezafibrate IR | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
489 | Bezafibrate SR | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
490 | Bezafibrate, Beza, BZF, Bezalip | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
491 | Bezafibrate, Beza, BZF, Bezalip mono | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
492 | Bezalip | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 3件: 93 93, 94, 160 |
493 | Bezalip mono | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 93 93 |
494 | Bezalip Retard | 1件: Bezafibrate Bezafibrate | 1件: D01366
D01366
| 1件: PPARA PPARA 💬 | 10件: Adipocytokine signaling pathway Adipocytokine signaling pathway, Alcoholic liver disease, Chemical carcinogenesis - receptor activation, Diabetic cardiomyopathy, Glucagon signaling pathway, Hepatitis C, Insulin resistance, Non-alcoholic fatty liver disease, PPAR signaling pathway, cAMP signaling pathway 💬 | 1件: 160 160 |
495 | Bezlotoxumab | 1件: Bezlotoxumab Bezlotoxumab | 1件: D10453
D10453
| - | - | 2件: 96 96, 97 |
496 | BF 2.649 | - | - | - | - | 1件: 6 6 |
497 | BF 2.649 10 mg | - | - | - | - | 1件: 6 6 |
498 | BF 2.649 20 mg | - | - | - | - | 1件: 6 6 |
499 | BF 2.649 40 mg | - | - | - | - | 1件: 6 6 |
500 | BF 2.649 5 mg | - | - | - | - | 1件: 6 6 |
501 | BF2.649 | 1件: Pitolisant Pitolisant | 1件: D10749
D10749
| 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
502 | BF2.649 (Pitolisant) | 1件: Pitolisant Pitolisant | 1件: D10749
D10749
| 1件: HRH3 HRH3 💬 | 1件: Neuroactive ligand-receptor interaction Neuroactive ligand-receptor interaction 💬 | 1件: 6 6 |
503 | BFAHF-2 | - | - | - | - | 1件: 96 96 |
504 | BFGF | 1件: Basic Fibroblast Growth Factor Basic Fibroblast Growth Factor | - | - | - | 1件: 56 56 |
505 | BG-12 120 | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
506 | BG00002 | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
507 | BG00002 (natalizumab) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
508 | BG00002-E (natalizumab high titer) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
509 | BG00011 | - | - | - | - | 1件: 85 85 |
510 | BG00012 | - | - | - | - | 2件: 13 13, 46 |
511 | BG00012 (DMF) | - | - | - | - | 1件: 13 13 |
512 | BG00012 (DMF) (Tecfidera®.) | - | - | - | - | 1件: 13 13 |
513 | BG0002 (natalizumab) | 1件: Natalizumab Natalizumab | 1件: D06886
D06886
| 1件: ITGA4 ITGA4 💬 | 14件: Arrhythmogenic right ventricular cardiomyopathy Arrhythmogenic right ventricular cardiomyopathy, Cell adhesion molecules, Dilated cardiomyopathy, ECM-receptor interaction, Focal adhesion, Hematopoietic cell lineage, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, PI3K-Akt signaling pathway, Regulation of actin cytoskeleton, Yersinia infection 💬 | 1件: 13 13 |
514 | BG9418 (interferon beta 1-a) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 1件: 13 13 |
515 | BG9418 (interferon beta-1a) | 1件: Interferon beta-1a Interferon beta-1a | 1件: D04554
D04554
| 2件: IFNAR1 IFNAR1, IFNAR2 💬 | 18件: Coronavirus disease - COVID-19 Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, Epstein-Barr virus infection, Hepatitis B, Hepatitis C, Herpes simplex virus 1 infection, Human papillomavirus infection, Influenza A, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Measles, NOD-like receptor signaling pathway, Natural killer cell mediated cytotoxicity, Necroptosis, Osteoclast differentiation, PI3K-Akt signaling pathway, Pathways in cancer, Toll-like receptor signaling pathway 💬 | 2件: 13 13, 97 |
516 | BG9924 | 1件: Baminercept Baminercept | 1件: D08866
D08866
| 1件: LTB |